Medications for Obesity

10 results

  • amphetamine sulfate

    (Amphetamine Sulfate)
    Granules Pharmaceuticals Inc.
    Amphetamine sulfate tablets are indicated for narcolepsy, Attention Deficit Disorder with Hyperactivity in conjunction with a comprehensive treatment program, and as a short-term adjunct for exogenous obesity in patients not responding to other weight loss strategies.

  • amphetamine sulfate

    (amphetamine sulfate)
    Lannett Company, Inc.
    Amphetamine sulfate tablets (5 mg and 10 mg) are indicated for narcolepsy, Attention Deficit-Disorder with Hyperactivity as part of a comprehensive treatment program, and short-term management of exogenous obesity as an adjunct to a caloric restriction regimen in patients unresponsive to other therapies.

  • contrave

    (naltrexone hydrochloride and bupropion hydrochloride)
    Nalpropion Pharmaceuticals LLC
    CONTRAVE is indicated for chronic weight management in adults with a BMI of 30 kg/m² or greater (obese) or 27 kg/m² or greater (overweight) with weight-related comorbid conditions, as an adjunct to diet and exercise. Safety with other weight loss products is not established.

  • diethylpropion hydrochloride

    (Diethylpropion Hydrochloride)
    Lannett Company, Inc.
    Diethylpropion hydrochloride extended-release tablets, 75 mg, are indicated for short-term management of exogenous obesity in patients with a BMI of 30 kg/m² or higher who have not responded to diet and exercise alone. It is intended for use as monotherapy.

  • lomaira

    (Phentermine Hydrochloride)
    KVK-Tech Inc
    LOMAIRA™ tablets are indicated for short-term weight reduction as an adjunct to exercise, behavioral modification, and caloric restriction in patients with a body mass index (BMI) of ≥30 kg/m², or ≥27 kg/m² with risk factors like controlled hypertension, diabetes, or hyperlipidemia.

  • phentermine hydrochloride

    (phentermine hydrochloride)
    SUNRISE PHARMACEUTICAL, INC.
    Phentermine hydrochloride capsules are indicated as a short-term adjunct to weight reduction programs, including exercise, behavioral modification, and caloric restriction, for patients with exogenous obesity (BMI ≥ 30 kg/m² or ≥ 27 kg/m² with risk factors like hypertension, diabetes, or hyperlipidemia).

  • saxenda

    (liraglutide)
    Novo Nordisk
    SAXENDA is indicated for weight management in adults and patients aged 12 and older with obesity (≥60 kg) or with overweight plus a weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity. Coadministration with other liraglutide-containing products is not recommended.

  • wegovy

    (semaglutide)
    Novo Nordisk
    WEGOVY is indicated for reducing major cardiovascular event risk in adults with obesity or overweight and cardiovascular disease, and for long-term weight reduction in adults and pediatric patients (12 years and older) with obesity or adults with overweight and weight-related comorbidities, alongside diet and exercise.

  • xenical

    (orlistat)
    H2-Pharma LLC
    XENICAL is indicated for managing obesity through weight loss and maintenance, alongside a reduced-calorie diet. It also helps prevent weight regain post-weight loss and is suitable for obese patients with a BMI ≥30 kg/m² or ≥27 kg/m² with additional risk factors like hypertension, diabetes, or dyslipidemia.

  • zepbound

    (tirzepatide)
    Eli Lilly and Company
    ZEPBOUND® is indicated for weight reduction and long-term maintenance in adults with obesity or overweight plus weight-related conditions, and for treating moderate to severe obstructive sleep apnea in obese adults, alongside a reduced-calorie diet and increased physical activity. Coadministration with other tirzepatide or GLP-1 products is not recommended.